Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meta-Analyses Will Get Separate Guidance Documents From FDA And IoM

Executive Summary

The question of how to develop meta-analyses of clinical trials that can yield useful information on drug and biologic safety will be the subject of an FDA guidance and an important focus of two reports from the Institute of Medicine

You may also be interested in...



Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible

To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.

Clinical Safety Assessments Need Formal Protocols, FDA Says; Guidance On "Synthesis" Possible

To obtain information suitable for regulatory decision-making on a drug's safety, FDA expects the assessment of data across clinical trials to be based on a formal protocol that specifies the rules for collecting, analyzing and reporting the information.

FDA Seeks Dedicated Meta-Analysis Team As Part Of PDUFA V User Fee Funding

FDA wants to create a meta-analysis team to conduct its own studies with funding from the next round of application user fees.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel